Lyme disease: a turning point

References

• Stricker RB, Lautin A, Burrascano JJ. Lyme disease: point/counterpoint. Expert Rev. Anti Infect. Ther.3, 155–165 (2005).
   PubMedGoogle Scholar
• Harvey WT, Salvato P. ‘Lyme disease’: ancient engine of an unrecognized borreliosis pandemic? Med. Hypotheses60, 742–759 (2003).
   PubMed Web of Science ®Google Scholar
• Wormser GP, Dattwyler RJ, Shapiro ED et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis.41, 1089–1134 (2006).
   Web of Science ®Google Scholar
• Cameron D, Gaito A, Harris N et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev. Anti Infect. Ther.2(1 Suppl.), S1–S13 (2004).
   PubMedGoogle Scholar
• Phillips SE, Harris NS, Horowitz R, Johnson L, Stricker RB. Lyme disease: scratching the surface. Lancet366, 1771 (2005).
   PubMedGoogle Scholar
• Phillips SE, Burrascano JJ, Harris NS, Johnson L, Smith PV, Stricker RB. Chronic infection in ‘post-Lyme borreliosis syndrome’. Int. J. Epidemiol.34, 1439–1440 (2005).
   PubMedGoogle Scholar
• Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum.48, 534–540 (2003).
   PubMedGoogle Scholar
• Kalish RS, Wood JA, Golde W et al. Human T lymphocyte response to Borrelia burgdorferi infection: no correlation between human leukocyte function antigen type 1 peptide response and clinical status. J. Infect. Dis.187, 102–108 (2003).
   PubMed Web of Science ®Google Scholar
• Casjens S, Palmer N, van Vugt R et al. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol. Microbiol.35, 490–516 (2000).
   PubMed Web of Science ®Google Scholar
• Embers ME, Ramamoorthy R, Philipp MT. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. Microbes Infect.6, 312–318 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson L, Stricker RB. Treatment of Lyme disease: a medicolegal assessment. Expert Rev. Anti Infect. Ther.2, 533–557 (2004).
   PubMedGoogle Scholar
• Yrjänäinen H, Hytönen J, Song XY, Oksi J, Hartiala K, Viljanen MK. Anti-tumor necrosis factor-α treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. J. Infect. Dis.195, 1489–1496 (2007).
   PubMedGoogle Scholar
• Steinbrook R. Guidance for guidelines. N. Engl. J. Med.356, 331–333 (2007).
   PubMed Web of Science ®Google Scholar
• Klempner MS, Hu LT, Evans J et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med.345, 85–92 (2001).
   PubMed Web of Science ®Google Scholar
• Lorber B. Update in infectious diseases. Ann. Intern. Med.137, 974–980 (2002).
   PubMedGoogle Scholar
• Radolf J. Posttreatment chronic Lyme disease – what it is not. J. Infect. Dis.192, 948–949 (2005).
   PubMedGoogle Scholar
• Cameron DJ. Generalizability in two clinical trials of Lyme disease. Epidemiol. Perspect. Innov.3, 12–18 (2006).
   PubMedGoogle Scholar
• Krupp LB, Hyman LG, Grimson R et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology60, 1923–1930 (2003).
   PubMed Web of Science ®Google Scholar
• Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South. Med. J.98, 590–595 (2005).
   PubMed Web of Science ®Google Scholar
• Fallon BA, Keilp JG, Corbera KM et al. A randomized, placebo-controlled trial of repeated intravenous antibiotic therapy for Lyme encephalopathy. Neurology (In press).
   Google Scholar
• Keilp JG, Corbera K, Slavov I, Taylor MJ, Sackeim HA, Fallon BA. WAIS-III and WMS-III performance in chronic Lyme disease. J. Int. Neuropsychol. Soc.12, 119–129 (2006).
   PubMed Web of Science ®Google Scholar
• Cameron DJ. Results from Lyme disease treatment trial. Presented at: Columbia University/LDA Conference, Lyme and Other Tick-Borne Diseases: Emerging Tick-Borne Diseases. Philadelphia, PA, USA, October 28, 2005.
   Google Scholar
• Cameron DJ. Consequences of treatment delay in Lyme disease. J. Eval. Clin. Practice13, 470–472 (2007).
   PubMed Web of Science ®Google Scholar
• Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin. Infect. Dis.45, 149–157 (2007).
   PubMed Web of Science ®Google Scholar
• Von Lackum K, Babb K, Riley SP, Wattier RL, Bykowski T, Stevenson B. Functionality of Borrelia burgdorferi LuxS: the Lyme disease spirochete produces and responds to the pheromone autoinducer-2 and lacks a complete activated-methyl cycle. Int. J. Med. Microbiol.296(Suppl. 40), 92–102 (2006).
   PubMedGoogle Scholar
• Bulut Y, Faure E, Thomas L, Equils O, Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J. Immunol.167, 987–994 (2001).
   PubMed Web of Science ®Google Scholar
• Lella RK, Sharma C. EIS (enhanced intracellular survival) protein of Mycobacterium tuberculosis disturbs the cross regulation of T-cells. J. Biol. Chem.282, 18671–18675 (2007).
   PubMedGoogle Scholar
• Salazar JC, Pope CD, Moore MW, Pope J, Kiely TG, Radolf JD. Lipoprotein-dependent and -independent immune responses to spirochetal infection. Clin. Diagn. Lab. Immunol.12, 949–958 (2005).
   PubMedGoogle Scholar
• Ghigo E, Capo C, Raoult D, Mege JL. Interleukin-10 stimulates Coxiella burnetii replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever. Infect. Immun.69, 2345–2352 (2001).
   PubMedGoogle Scholar